Strategy and business model

To fulfill its ambition of becoming the world leader in genome engineering and the gold-standard for genome surgery, Cellectis has devised and implemented a clear strategy that involves concentrating its efforts in its field of excellence – designing and manufacturing genome programming systems.

Cellectis implements its strategy by:

• prioritizing meganucleases for therapeutic applications in order to treat orphan genetic diseases and certain viral infections, and to develop new products to fight cancer or to improve allogeneic transplantation.

• pro-actively transferring its technology to major academic and industrial laboratories as a research tool.

• signing business agreements in its four target application fields: healthcare, biotechnology, agricultural biotechnology and research.

• forging wider agricultural biotechnology partnerships with stakeholders in the field.

• and finally sustaining its competitive advantage by continuing to enhance its research, its patent portfolio and increasing its technological lead and expertise